Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Quipt Home Medical Corp T.QIPT

Alternate Symbol(s):  QIPT

Quipt Home Medical Corp. is a home medical equipment provider. The Company specializes in improving the home management of chronic illness through the application of telehealth systems and automated distribution. It provides in-home monitoring and disease management services, including end-to-end respiratory solutions for patients in the United States. It offers nebulizers, oxygen concentrators, continuous positive airway pressure (CPAP) and Bilevel Positive Airway Pressure (BiPAP) units; traditional and non-traditional medical respiratory equipment and services, and non-invasive ventilation equipment, supplies, and services. The Company's product offerings include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. Its products and services consist of sleep apnea and pap treatment, home ventilation, daily and ambulatory aides, and respiratory equipment rental.


TSX:QIPT - Post by User

Comment by lscfaon Feb 01, 2021 3:45pm
172 Views
Post# 32439277

RE:M PARTNERS, $3.50PT

RE:M PARTNERS, $3.50PT

2022 ebitda forecast = $3.50 x 112.5 mil shs / 11 multiple = $35.8 mil vs. $20.8 mil for 2020, 72% growth over 2 years.    



Additionally, Protech is currently pursuing an uplisting to the NASDAQ which will increase PTQ’s exposure and accessibility to U.S. capital markets. As a result, we believe Protech presents a unique buying opportunity ahead of U.S. institutional fund flows. We are maintaining our BUY recommendation and increasing our target price to $3.50/share (from $2.50/share) based on 11x 2022 EBITDA (from 9x 2021 EBITDA).

<< Previous
Bullboard Posts
Next >>